Skip to main content

Regenxbio

REGENXBIO Inc is an American clinical-stage biotechnology company focused on developing AAV-based gene therapy candidates for rare genetic and retinal diseases. The company utilizes its proprietary NAV Technology platform to engineer adeno-associated virus vectors for targeted therapeutic delivery. Principal revenue is derived from technology licensing royalties, commercial milestone payments, and collaborative research agreements with biopharmaceutical partners. Core end markets serve ophthalmology practices, pediatric neurology centers, and specialized rare disease clinical facilities globally. REGENXBIO holds a pioneer position in the biopharmaceutical industry as a foundational licensor of AAV gene delivery technologies. The company is headquartered in Rockville, Maryland, and its common stock trades on the Nasdaq Global Select Market.

3 of the funds FundTelligence covers report a position in Regenxbio.

Legal name
Regenxbio Inc
Sector
Health Care
Country
United States
Funds holding it
3
Exposure themes
Gene Therapy, Genetic Medicine, Precision Medicine & Genomics

Funds holding Regenxbio

Loading...